Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Stage IVA Pancreatic Cancer
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IVB Pancreatic Cancer
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Health Care Provider
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Malignant Brain Neoplasm
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
- Malignant Genitourinary System Neoplasm
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. Evaluate patient perceptions surrounding their quality of life (QOL) prior to pharmacogenomics (PGx) testing and 3 months post PGx testing. II. Understand the clinical utility/relevancy of PGx testing in cancer patients at Mayo Clinic Arizona from the viewpoint of their provid...
PRIMARY OBJECTIVES: I. Evaluate patient perceptions surrounding their quality of life (QOL) prior to pharmacogenomics (PGx) testing and 3 months post PGx testing. II. Understand the clinical utility/relevancy of PGx testing in cancer patients at Mayo Clinic Arizona from the viewpoint of their providers. OUTLINE: Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing. After completion of study, patients are followed for up to 1 year.
Tracking Information
- NCT #
- NCT04067960
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Niloy J Samadder Mayo Clinic
Get Well Soon